Disease Domain | Count |
---|---|
Neoplasms | 9 |
Endocrinology and Metabolic Disease | 4 |
Nervous System Diseases | 2 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic radiopharmaceuticals | 7 |
Diagnostic radiopharmaceuticals | 5 |
Peptide Conjugate Radionuclide | 2 |
Small molecule drug | 2 |
Fab fragment | 1 |
Target |
Mechanism SSTR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism PSMA inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
68Ga-Edotreotide ( SSTR ) | Gastro-Enteropancreatic Neuroendocrine Tumor More | Approved |
ITM-24D | Prostatic Cancer More | Phase 3 |
Lutetium (177Lu) edotreotide ( SSTR ) | Gastro-Enteropancreatic Neuroendocrine Tumor More | Phase 3 |
ITM-55D ( FOLR1 ) | Ovarian Cancer More | Phase 1 |
Gallium-68 DOTA-Zoledronate(University Medicine of the Johannes Gutenberg-University Mainz) | Diagnostic agents More | Phase 1 |